NALMEFENE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nalmefene Hydrochloride, and what generic alternatives are available?
Nalmefene Hydrochloride is a drug marketed by Chengdu Shuode and Purdue Pharma Lp and is included in two NDAs.
The generic ingredient in NALMEFENE HYDROCHLORIDE is nalmefene hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nalmefene Hydrochloride
A generic version of NALMEFENE HYDROCHLORIDE was approved as nalmefene hydrochloride by PURDUE PHARMA LP on February 8th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NALMEFENE HYDROCHLORIDE?
- What are the global sales for NALMEFENE HYDROCHLORIDE?
- What is Average Wholesale Price for NALMEFENE HYDROCHLORIDE?
Summary for NALMEFENE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Clinical Trials: | 31 |
| Patent Applications: | 165 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NALMEFENE HYDROCHLORIDE |
| DailyMed Link: | NALMEFENE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NALMEFENE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tharimmune Inc | Phase 1 |
| Purdue Pharma LP | Phase 4 |
| Nantes University Hospital | Phase 3 |
Pharmacology for NALMEFENE HYDROCHLORIDE
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for NALMEFENE HYDROCHLORIDE
US Patents and Regulatory Information for NALMEFENE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-001 | Nov 15, 2023 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-002 | Nov 15, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Purdue Pharma Lp | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 212955-001 | Feb 8, 2022 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
